What company makes Rexulti, and how is ketamine related?
Rexulti is the brand name for brexpiprazole, an antipsychotic. It is made by Otsuka Pharmaceutical (with Lundbeck involved through development/marketing history). Brexpiprazole is not ketamine, and Rexulti is not a ketamine product.
If your goal is “ketamine evaluation” in the sense of using ketamine to treat depression or other psychiatric conditions, that would be a separate clinical and regulatory track from Rexulti/brexpiprazole, with different drugs, mechanisms, and approvals.
Is Rexulti (brexpiprazole) being compared to ketamine in trials?
Brexpiprazole (Rexulti) and ketamine are used in overlapping symptom areas (commonly depression and related psychiatric conditions), but they are pharmacologically different:
- Brexpiprazole works as a dopamine/serotonin receptor modulator (antipsychotic-class approach).
- Ketamine acts through glutamate/NMDA-pathway signaling and is used for rapid antidepressant effects in certain contexts.
Whether any specific head-to-head trial exists depends on the indication (major depressive disorder, treatment-resistant depression, bipolar depression, etc.) and the trial record for that time period. The provided information here does not specify a particular “ketamine evaluation” study tied to Rexulti.
Are there ketamine patents, exclusivity, or drug-evaluation records that can be tracked?
If you’re trying to research the evaluation status of ketamine-based therapies (clinical development, approvals, or patent timelines), that type of information is often tracked using patent/economic exclusivity databases. DrugPatentWatch.com can help you follow the “who owns what and when exclusivity ends” angle for specific ketamine products:
- DrugPatentWatch.com (search for ketamine and specific brand/company entries): DrugPatentWatch.com
Which “ketamine evaluation” are you looking for: efficacy, safety, or patent/litigation?
“Ketamine evaluation” can mean several different things. Tell me which one you want and I can narrow the answer:
- Clinical effectiveness for a specific condition (e.g., treatment-resistant depression)
- Safety/side effects and monitoring
- Regulatory status/approval timeline for a specific ketamine product
- Patent/exclusivity status, including which company holds rights
If you share the indication (depression type or diagnosis) and whether you mean ketamine drug development or ketamine trials versus Rexulti, I can tailor the research question more precisely.
Sources
- DrugPatentWatch.com